for people ages 18 years and up (full criteria)
at San Diego, California and other locations
study started
estimated completion



Phase 1 study comprised of open-label, dose escalation, multiple cohorts of P-BCMA-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed / refractory Multiple Myeloma (RRMM).

Official Title

Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-BCMA-ALLO1 in Subjects With Relapsed / Refractory Multiple Myeloma (MM)


Phase 1 study follows a 3+3 design of dose-escalating cohorts. After a subject enrolls, allogeneic CAR-T cells will be administered as a single dose, following a standard chemotherapy based conditioning regimen. Treated subjects will undergo serial measurements of safety, tolerability and response. Rimiducid may be administered as indicated.


Multiple Myeloma Neoplasms, Plasma Cell P-BCMA-ALLO1 CAR-T cells Rimiducid P-BCMA-ALLO1 CAR-T cells (single dose)


You can join if…

Open to people ages 18 years and up

  1. Must have signed written, informed consent.
  2. Males or females, ≥18 years of age.
  3. Must have a confirmed diagnosis of active MM.
  4. Must have measurable MM.
  5. Must have relapsed / refractory MM, having received treatment with a proteasome inhibitor, immunomodulatory agent (IMiD), and anti-CD38 therapy.
  6. Must be willing to practice birth control from the time of Screening and throughout the first year of the study after P-BCMA-ALLO1 administration.
  7. Must have a negative serum pregnancy test at Screening and a negative urine pregnancy test within 3 days prior to initiating the lymphodepletion chemotherapy regimen (females of childbearing potential).
  8. Must be at least 90 days since autologous stem cell transplant, if performed.
  9. Must have adequate vital organ function within pre-determined parameters.
  10. . Must have recovered from toxicities due to prior therapies.
  11. . Must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.

You CAN'T join if...

  1. Is pregnant or lactating.
  2. Has inadequate venous access.
  3. Has active hemolytic anemia, plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome, disseminated intravascular coagulation, leukostasis, or amyloidosis.
  4. Has an active second malignancy (not disease-free for at least 5 years) in addition to MM, excluding low-risk neoplasms such as non-metastatic basal cell or squamous cell skin carcinoma.
  5. Has active autoimmune disease.
  6. Has a history of significant central nervous system (CNS) disease, such as stroke, epilepsy, etc.
  7. Has an active systemic infection.
  8. Has a history of hepatitis B, hepatitis C virus, human immunodeficiency virus (HIV), or human T-lymphotropic virus (HTLV) infection, or any immunodeficiency syndrome.
  9. Has New York Heart Association (NYHA) Class III or IV heart failure, unstable angina, or a history of myocardial infarction or significant arrhythmia.
  10. . Has any psychiatric or medical disorder that would preclude safe participation in and/or adherence to the protocol.
  11. . Has received prior gene therapy or gene-modified cellular immunotherapy or T cell engaging antibodies.
  12. . Has received anti-cancer medications within 2 weeks of the time of initiating conditioning chemotherapy.
  13. . Has received immunosuppressive medications within 2 weeks of the time of administration of P-BCMA-ALLO1, and/or expected to require them while on study.
  14. . Has received systemic corticosteroid therapy within 1 week or 5 half-lives (whichever is shorter) of the administration of P-BCMA-ALLO1 or is expected to require it during the course of the study.
  15. . Has CNS metastases or symptomatic CNS involvement of their myeloma.
  16. . Has a history of severe immediate hypersensitivity reaction to any of the agents used in this study.
  17. . Has a history of having undergone allogeneic stem cell transplantation, or any other allogeneic or xenogeneic transplant, or has undergone autologous transplantation within 90 days.


  • University of California San Diego
    San Diego California 92093 United States
  • Advocate Aurora Health
    Park Ridge Illinois 66068 United States


not yet accepting patients
Start Date
Completion Date
Poseida Therapeutics, Inc.
Phase 1
Study Type
Last Updated